Aerobiotix produces medical-grade air disinfection systems, including its Illuvia® ultraviolet photolytic chamber product, designed to break pathogen DNA and reduce healthcare-acquired infections. Its devices combine ultraviolet light, HEPA filters, and proprietary filtration to remove bacteria, viruses, VOCs and other contaminants, and are designed to run continuously in occupied rooms. The company reports its solutions are already being used in over 170 healthcare locations and include integrated tracking to help facilities measure and manage air quality. Aerobiotix says its technology can be applied beyond healthcare to schools, high-density residential, and commercial office buildings. Management plans to expand market share and develop additional indoor air quality solutions to meet surging demand. Prominent investors in the company include Vivo Capital and Asahi Kasei Corporate Venture Capital. Aerobiotix, founded in 2013 and based in Miamisburg, Ohio, is a global medical company that develops hospital-based airborne infection control products. The company has FDA 510(k) cleared air decontamination devices, including the operating-room ILLUVIA system, which use mechanical and ultraviolet filtration to reduce bacterial and viral contamination including SARS-CoV-2. Its devices are supported by multiple peer-reviewed research studies and include real-time air quality monitoring and internet-of-medical-things connectivity. Aerobiotix products have been used to support thousands of procedures across multiple surgical specialties and are deployed in over 175 hospitals and multiple long-term care facilities. The company raised $25 million in growth equity financing led by Vivo Capital with participation from Asahi Kasei Ventures. The new funding will be used to accelerate sales, marketing, and new product development to expand commercial traction domestically and internationally.

Total raised

$35M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Mar 2022